Find the tests you need to diagnose and manage arthritis

Couples dancing outdoors

Early detection can make all the difference

Many forms of arthritis can be difficult to diagnose. Nevertheless, early detection can be critical in preventing or delaying the onset of joint damage and disability. 

For example, many symptoms of osteoarthritis (OA) and rheumatoid arthritis (RA) overlap, including pain and stiffness in the joints. Yet in RA, irreversible joint destruction and deformity can occur in as little as six months from onset of symptoms.1

To differentiate between OA and RA, and also help detect RA early, Quest Diagnostics is the only lab to offer novel RA testing that includes a biomarker specific to the joint to help differentiate RA from OA. Our entire immunology menu is designed with the needs of you and your patients in mind.

Get guidelines-based testing

You can be confident that you’re ordering tests based on clinical guidelines and publications when you test with us. Our menus conform to the recommendations of the American College of Rheumatology, European League Against Rheumatism and American Academy of Family Physicians.

Arthritis testing from diagnosis to prognosis and monitoring, you’re covered

From first-line tests to monitoring of arthritis, turn to Quest for the right test for the right patient at the right time. Our immunology test menu includes important markers for diagnosis and monitoring, such as antinuclear antibody, C-reactive protein, cyclic citrullinated peptide (CCP) antibody and rheumatoid factor.

Our broader menu allows you to test for other risks that may interfere with some of today’s therapeutic options, including tuberculosis testing with QuantiFERON®-TB Gold, and viral, bacterial and fungal infection testing.

Another example is Quest genotyping for HLA-B*5801. The presence of HLA-B*5801 is highly associated with hypersensitivity to allopurinol, a common treatment for gout. The ACR guidelines recommend HLA-B*5801 genotyping prior to beginning allopurinol therapy in high-risk populations, i.e. those with a high HLA-B*5801 allele frequency, Koreans with Stage 3 or worse chronic kidney disease and all patients of Han Chinese and Thai descent. The Clinical Pharmacogenomics Implementation Consortium therefore recommends HLA-B*5801 testing for any patient being considered for allopurinol. If the results are positive, the patient should receive an alternate treatment.

You can also look to Quest for all the routine tests commonly used to follow up with arthritis patients, including urinalysis, CBC, blood chemistry and immunology tests.

Download our Immunology/Rheumatology test menu

For handy reference, print and post this Quest Diagnostics complete Immunology/Rheumatology test menu.

Learn more about these important new tests

Gain access to new and innovative tests that meet the Quest Diagnostics standard for clinical validation and actionability. View comprehensive summaries for each of the following:

  • 14-3-3 eta Protein detects an inflammatory mediator, 14-3-3 eta, known to contribute to the pathophysiology of rheumatoid arthritis. This new biomarker indicates more severe disease in both early and established disease
  • Rheumatoid Arthritis Diagnostic Panel IdentRA™ with 14-3-3 eta—three-marker panel that can help differentiate RA from other inflammatory diseases
  • HLA-B27 Antigen—can aid in the diagnosis of ankylosing spondylitis
  • HLA B*5801—can indicate possible severe skin reactions to allopurinol, a common treatment for gout
  • ANCA—can help diagnose vasculitis disease, inflammatory bowel disease and other autoimmune diseases



    We’re here to help you manage patients with arthritis

       Call icon Contact us by phone
Call 1.866.MY.QUEST (1.866.697.8378)
       Contact us icon Contact a Sales Representative 
       View icon See our physician resources to learn more about arthritis
       Download icon Download our Immunology or Rheumatology requisition for
easy ordering



1. The primary care physician's guide to inflammatory arthritis: Diagnosis. Rheumatology Network website. Published June 2, 2010. Accessed September 17, 2015.